Cardiff Oncology Announces Clinical Data In Pancreatic Cancer And Small Cell Lung Cancer, Including Single-Agent Activity From Onvansertib Monotherapy
Portfolio Pulse from Happy Mohamed
Cardiff Oncology, Inc. (NASDAQ:CRDF) has announced positive clinical data from its ongoing trials of onvansertib monotherapy and combination therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC) and small cell lung cancer (SCLC). The company also plans to initiate a first-line trial for mPDAC. The data from the trials show promising results, with the pancreatic cancer Phase 2 trial showing greater efficacy compared to historical controls. The company will hold a conference call to discuss the preliminary data.
September 26, 2023 | 8:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cardiff Oncology's positive clinical trial results for onvansertib in treating pancreatic and lung cancer could potentially boost investor confidence and the company's stock price.
Positive clinical trial results are typically seen as a positive indicator for biotech companies, as they suggest the potential for future revenue from the drug being tested. This could lead to increased investor confidence in Cardiff Oncology and a potential rise in its stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100